NEFL and Huntington disease: The establishment of these standard disease stages in HD underscores the growing importance of biological markers in the diagnosis and treatment of HD and further suggests the future feasibility of screening for early HD through molecular biomarkers such as neurofilament light chain (NfL) [5].